1 | Fampyra 10mg prolonged release tablets | [2] Dalfampridine Dalfampridine, Manganese citrate | [1] D04127
D04127
| [4] KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | [4] Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | [1] 13 13 |
2 | Mezavant Gastro-resistant, prolonged release tablets | [2] Manganese citrate Manganese citrate, Mesalazine | [1] D00377
D00377
| - | - | [1] 97 97 |
3 | Mezavant XL 1200 mg gastro-resistant prolonged release tablets | [2] Manganese citrate Manganese citrate, Mesalazine | [1] D00377
D00377
| - | - | [1] 97 97 |
4 | Mezavant XL 1200 mg gastro-resistant, prolonged release tablets | [2] Manganese citrate Manganese citrate, Mesalazine | [1] D00377
D00377
| - | - | [1] 97 97 |
5 | Mezavant XL 1200 mg gastro-resistant, prolonged release tablets. | [2] Manganese citrate Manganese citrate, Mesalazine | [1] D00377
D00377
| - | - | [1] 97 97 |
6 | Mezavant XL 1200mg gastro-resistant, prolonged release tablets | [2] Manganese citrate Manganese citrate, Mesalazine | [1] D00377
D00377
| - | - | [1] 97 97 |
7 | Mezavant XL Gastro-resistant, prolonged release tablets | [2] Manganese citrate Manganese citrate, Mesalazine | [1] D00377
D00377
| - | - | [1] 97 97 |
8 | Oxycodone naloxone prolonged release tablets | [2] Naloxone Naloxone, Oxycodone | [5] D01340
D01340
,
D03783
,
D05312
,
D05462
,
D08249
| [3] OPRD1 OPRD1, OPRK1, OPRM1 💬 | [5] Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 226 226 |
9 | Oxycodone/Naloxone Prolonged Release tablets | [2] Naloxone Naloxone, Oxycodone | [5] D01340
D01340
,
D03783
,
D05312
,
D05462
,
D08249
| [3] OPRD1 OPRD1, OPRK1, OPRM1 💬 | [5] Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 6 6 |
10 | Oxycodone/naloxone prolonged release tablets 10 mg /5 mg | [3] Manganese citrate Manganese citrate, Naloxone, Oxycodone | [5] D01340
D01340
,
D03783
,
D05312
,
D05462
,
D08249
| [3] OPRD1 OPRD1, OPRK1, OPRM1 💬 | [5] Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 6 6 |
11 | Oxycodone/naloxone prolonged release tablets 10/5 mg | [3] Manganese citrate Manganese citrate, Naloxone, Oxycodone | [5] D01340
D01340
,
D03783
,
D05312
,
D05462
,
D08249
| [3] OPRD1 OPRD1, OPRK1, OPRM1 💬 | [5] Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 226 226 |
12 | Oxycodone/naloxone prolonged release tablets 20 mg /10 mg | [3] Manganese citrate Manganese citrate, Naloxone, Oxycodone | [5] D01340
D01340
,
D03783
,
D05312
,
D05462
,
D08249
| [3] OPRD1 OPRD1, OPRK1, OPRM1 💬 | [5] Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 6 6 |
13 | Oxycodone/naloxone prolonged release tablets 20/10 mg | [3] Manganese citrate Manganese citrate, Naloxone, Oxycodone | [5] D01340
D01340
,
D03783
,
D05312
,
D05462
,
D08249
| [3] OPRD1 OPRD1, OPRK1, OPRM1 💬 | [5] Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 226 226 |
14 | Oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg | [3] Manganese citrate Manganese citrate, Naloxone, Oxycodone | [5] D01340
D01340
,
D03783
,
D05312
,
D05462
,
D08249
| [3] OPRD1 OPRD1, OPRK1, OPRM1 💬 | [5] Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 6 6 |
15 | Oxycodone/naloxone prolonged release tablets 5/2.5 mg | [3] Manganese citrate Manganese citrate, Naloxone, Oxycodone | [5] D01340
D01340
,
D03783
,
D05312
,
D05462
,
D08249
| [3] OPRD1 OPRD1, OPRK1, OPRM1 💬 | [5] Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 226 226 |
16 | Prolonged release tablet | [1] Manganese citrate Manganese citrate | - | - | - | [1] 6 6 |
17 | Tofacitinib (Xeljanz®) 11mg Prolonged Release Tablet | [1] Tofacitinib Tofacitinib | [1] D09970
D09970
| [4] JAK1 JAK1, JAK2, JAK3, TYK2 💬 | [37] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | [1] 46 46 |
18 | Xeljanz® 11mg Prolonged Release Tablet | [2] Manganese citrate Manganese citrate, Tofacitinib | [1] D09970
D09970
| [4] JAK1 JAK1, JAK2, JAK3, TYK2 💬 | [37] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | [1] 46 46 |